Please login to the form below

Not currently logged in
Email:
Password:

PRA opens Beijing office to expand Chinese operations

New office adds to the CRO's existing base in Shanghai

PRA has expanded its operations in China and opened a new office in Beijing to expand its presence in the country and add to its existing Shanghai office.

The move caps an already busy year for the US-based contract research organisation (CRO), which has so far opened new offices in the UK, the Netherlands and Singapore during 2012.

Helen Neal, regional director – clinical operations, Asia Pacific, Middle East, and North Africa, said: “As the demand for clinical sites in Asia increase, we continually strive to strengthen our existing operations in China and the Asia Pacific region. 

“By adding more professional staff and locations, we can give our clients greater access to these critical markets and geography. In addition to our expansion in China, we continue to increase our presence into new and emerging South East Asian regions for access to patients and resources.”

The company said the move would particularly help it boost local project teams' ability to meet the growing demand for clinical drug development programmes.

Kent Thoelke, executive VP of scientific and medical affairs, said: “In order for global drug development to continue successfully, the need to access patients at high-quality ICH/GCP sites in emerging regions like China is critical.

“PRA's expansion in this market gives us the ability to bring exciting new clinical trials to a much broader market in China, while providing even greater patient access to our clients and sponsor companies.”

PRA has been operating in China for over 10 years. In addition to an office in Hong Kong, the CRO also has Asia Pacific bases in countries such as South Korea, Taiwan, Thailand, Singapore, Australia, New Zealand, and India.

29th August 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Biosector 2

Biosector 2 (B2) is a global healthcare public relations agency that partners with visionary clients to deliver groundbreaking programs and...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...